Treadwell Therapeutics

About:

Treadwell Therapeutics is a clinical-stage oncology company that develops medicines to address unmet needs in patients with cancer.

Website: https://treadwelltx.com/

Top Investors: Adrian Cheng, Sino Biopharmaceutical, 3W Fund Management, TIO Bioventures, Prosperous Alliance Investments

Description:

Treadwell Therapeutics is a clinical-stage oncology company that develops medicines to address unmet needs in patients with cancer. Founded by a cadre of pre-eminent scientific luminaries, including Dr. Tak W. Mak, the Company's robust, internally developed pipeline includes a first-in-class PLK4 kinase inhibitor, CFI-400945, and a best-in-class TTK inhibitor, CFI-402257, and CFI-402411, an oral immunomodulatory kinase inhibitor with activity toward HPK1. Treadwell also has a robust pre-clinical pipeline with multiple biologic and next-generation TCR-based autologous cell therapy programs.